PIMECROLIMUS
Clinical safety rating
safeAnimal studies have demonstrated safety
Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.
| Metabolism | Primarily metabolized via hepatic cytochrome P450 3A4 (CYP3A4) to O-demethylated metabolites; also undergoes further hydroxylation and glucuronidation. |
| Excretion | Primarily fecal (78.4% of dose) via biliary excretion; renal elimination accounts for <1% of unchanged drug. |
| Half-life | Terminal elimination half-life is approximately 65 hours (range 22–115 hours) in adult atopic dermatitis patients, reflecting slow systemic clearance. |
| Protein binding | 99.5% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Approximately 1.3 L/kg (range 0.6–2.1 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Topical: Systemic bioavailability is very low (<0.5% of applied dose) based on blood concentration measurements. |
| Onset of Action | Topical: Improvement noted within 1 week of twice-daily application; measurable reduction in pruritus and erythema often seen by day 3–5. |
| Duration of Action | Topical: Duration of effect persists for the treatment period; clinical improvement sustained with continued use. Upon discontinuation, symptoms may recur within days to weeks. |
| Molecular Weight | 810.5 |
Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment; systemic absorption is minimal (<2.5%). |
| Liver impairment | No formal studies in hepatic impairment; based on minimal systemic absorption, no adjustment is likely required, but use caution in severe hepatic impairment due to theoretical risk of increased exposure. |
| Pediatric use | Children ≥2 years: Apply a thin layer of 1% cream to affected areas twice daily; maximum application area: <20% body surface area. Avoid use in children <2 years due to risk of systemic effects (insufficient data). |
| Geriatric use | No specific dose adjustment; use lowest effective amount due to potential for increased skin sensitivity and renal function decline with age. |
| 1st trimester | Limited human data; animal studies show no teratogenicity at systemic exposures similar to human therapeutic levels. Risk cannot be excluded. |
| 2nd trimester | Limited human data; no known risks from topical use due to minimal systemic absorption. Consider risk-benefit. |
| 3rd trimester | Limited human data; no known risks from topical use. Minimal systemic absorption suggests low risk. |
Clinical note
No significant drug interactions May increase risk of skin malignancies and lymphomas.
| Placental transfer | Based on molecular weight (810.5 Da) and low systemic bioavailability (<1% after topical application), placental transfer from topical use is expected to be negligible. However, no human data on placental transfer are available. |
| Breastfeeding | Topical pimecrolimus is unlikely to be excreted into breast milk in clinically significant amounts due to minimal systemic absorption. However, application to the breast should be avoided to prevent infant ingestion. Use with caution. |
| Lactation Rating | L3 - Probably Compatible (Moderately Safe) |
| Teratogenic Risk | Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: theoretical risk due to systemic absorption; avoid if possible. Second and third trimesters: limited data; risk of fetal harm cannot be excluded. |
| Fetal Monitoring | Monitor for signs of systemic infection or local skin reactions in the mother. Fetal monitoring not routinely required; however, if used extensively over large body surface areas, consider monitoring for potential adrenal suppression or immunosuppression in the neonate. |
| Fertility Effects | No specific human studies on fertility. Animal studies at high oral doses showed no impairment of fertility. Topical application is unlikely to affect fertility due to minimal systemic absorption. |
■ FDA Black Box Warning
Long-term safety of topical calcineurin inhibitors has not been established; rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported; avoid continuous long-term use; limit use to indicated short-term and intermittent treatment.
| Common Effects | Burning |
| Serious Effects |
Hypersensitivity to pimecrolimus or any component of the formulationNetherton syndrome (generalized erythroderma, lamellar ichthyosis)Skin infections (viral, bacterial, fungal) at the application site
| Precautions | Increased risk of infections (e.g., varicella zoster, herpes simplex); avoid use on active infections; possible lymphadenopathy; photosensitivity (avoid UV exposure); monitor for skin atrophy; not recommended in children <2 years; use during pregnancy only if clearly needed. |
| Food/Dietary | No known food interactions with topical pimecrolimus. Oral ingestion should be avoided; however, accidental small amounts on skin are unlikely to cause systemic effects. |
| Clinical Pearls | Pimecrolimus is a topical calcineurin inhibitor used for mild-to-moderate atopic dermatitis. It is not indicated for use in children under 2 years. Avoid use on infected skin; monitor for local irritation. Long-term safety concerns include potential increased risk of lymphoma and skin malignancies; use minimal amounts for shortest duration necessary. Do not use with occlusive dressings. Consider intermittent therapy for flares. |
| Patient Advice | Apply a thin layer only to affected areas, avoiding eyes, mouth, and broken skin. · Do not cover treated area with bandages or wraps unless directed by your doctor. · Wash hands after applying unless treating hands. · Avoid sun exposure, tanning beds, and UV therapy while using this medication. · Report any signs of infection, skin burning, or worsening rash. · Do not use for prolonged periods; use only until symptoms clear. · Inform your doctor if you are pregnant, breastfeeding, or have a weakened immune system. |
Loading safety data…